Randomized phase III Study of Adding Paclitaxel to Chemoradiotherapy With Capecitabine and Mitomycin C in Squamous Cell Anal Carcinoma
Clinical Colorectal Cancer · 2026
DOI: 10.1016/j.clcc.2026.01.002 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Colorectal Cancer, 2026. Verfasst von Sergey S Gordeyev und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Abdominal Oncology, No. 3 of N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Tyumen State Medical University, Moscow, Russ…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Anus Neoplasms, Carcinoma, Squamous Cell. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: In our pilot study adding paclitaxel to chemoradiotherapy (CRT) with capecitabine and mitomycin C (MMC) showed promising efficacy and we aimed to determine whether it could improve progression-free survival (PFS) in a randomized clinical trial setting. METHODS: We performed a randomized phase III trial at 2 centers. Enrolled patients with stage I-IIIB SCAC were randomly (1:1) allocated to either CRT with capecitabine and MMC (CRT-CM arm) or CRT with capecitabine, MMC and paclitaxel (CRT-CMP arm). The CRT-CMP regimen comprised 52 to 58 Gy IMRT, paclitaxel 45 mg/m2 on days 3, 10, 17, 24, 31, capecitabine 625 mg/m2 bid on treatment days and mitomycin C 10 g/m2 on day 1. The primary endpoint was PFS. Secondary endpoints were toxicity, overall survival (OS), complete clinical response (cCR) at 12 and 26 weeks. RESULTS: Between January 2016 and February 2020, 87 patients were enrolled in the CRT-CMP arm and 86 patients in the CRT-CM arm. The trial was stopped prematurely because MMC was no longer available in the country. Median follow-up was 50.3 months. Three-year PFS was 84.8% in the CRT-CMP arm and 66.9% in the CRM-CM arm (P = .009). Grade 3 or worse adverse events were observed in 45 (51.7%) patients in the CRT-CMP arm and in 20 (23.3%) patients in the CRT-CM arm (P < .0001). Seventy seven (89.5%) patients in the CRT-CMP arm and 63 (75.9%) patients in the CRM-CM arm had a cCR at 26 weeks (P = .024). CONCLUSION: Adding paclitaxel to CRT with capecitabine and MMC improves cCR rate and long-term outcomes in SCAC at the cost of higher toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Abdominal Oncology, No. 3 of N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Tyumen State Medical University, Moscow, Russia; Sechenov First Moscow State Medical University, Moscow, Russia. El…
- Department of Radiotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Sechenov First Moscow State Medical University, Moscow, Russia; Department of Oncoproctology, A.N. Ryzhikh National Medical Resear…
- Department of Antitumor Drug Therapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Department of Antitumor Drug Therapy, The Kommunarka Moscow Multidisciplinary Clinical Center, Moscow, Russia.
- Department of Oncoproctology, A.N. Ryzhikh National Medical Research Center of Coloproctology, Moscow, 123423, Russia.
- Department of Antitumor Drug Therapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
- Department of Radiotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
Zitieren
APA
Gordeyev, S. S., Chernykh, M. V., Fedyanin, M. Y., Rybakov, E. G., Besova, N. S., Ivanov, V. A., & Mamedli, Z. Z. (2026). Randomized phase III Study of Adding Paclitaxel to Chemoradiotherapy With Capecitabine and Mitomycin C in Squamous Cell Anal Carcinoma. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2026.01.002
Vancouver
Gordeyev SS, Chernykh MV, Fedyanin MY, Rybakov EG, Besova NS, Ivanov VA, et al. Randomized phase III Study of Adding Paclitaxel to Chemoradiotherapy With Capecitabine and Mitomycin C in Squamous Cell Anal Carcinoma. Clinical Colorectal Cancer. 2026. doi:10.1016/j.clcc.2026.01.002
BibTeX
@article{Gordeyev2026,
author = {Gordeyev, Sergey S and Chernykh, Marina V and Fedyanin, Mikhail Yu and Rybakov, Evgeny G and Besova, Nataliya S and Ivanov, Valerii A and Mamedli, Zaman Z},
title = {Randomized phase III Study of Adding Paclitaxel to Chemoradiotherapy With Capecitabine and Mitomycin C in Squamous Cell Anal Carcinoma},
journal = {Clinical Colorectal Cancer},
year = {2026},
doi = {10.1016/j.clcc.2026.01.002}
}
EUVIMED